公告称，收入增加主要是由于于报告期内，集团的VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系 统在全球商业化方面的持续推进促进了海外收入的大幅增长;及集团的AnchorMan®左心耳封堵系统及 AnchorMan®左心耳导引系统在中国和海外的商业化进展稳步推进。 智通财经APP讯，心通医疗-B(02160)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入2.29 亿元，同比增加2.67%;公司权益股东应占亏损216.3万元，同比减少96.17%;每股基本亏损0.09分。 ...

Core Viewpoint - The company anticipates a significant reduction in net loss for the first half of the year, projecting a loss not exceeding RMB 10 million, which represents a decrease of at least 83% compared to the same period last year [1] Group 1: Financial Performance - The expected net loss for the reporting period is projected to be less than RMB 10 million, marking a reduction of no less than 83% [1] - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty® transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions overseas, resulting in more than a twofold increase in overseas revenue compared to the same period last year [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its delivery system are making steady progress in commercialization in China, having received CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period in 2024 [1] Group 1: Financial Performance - The anticipated net loss reduction is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system in over 20 countries/regions [1] - Revenue from overseas markets has more than doubled compared to the six months ending June 30, 2024 [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its guiding system are making steady progress in commercialization in China [1] - The company obtained CE marking for the AnchorMan® system and has commenced commercialization in Europe during the reporting period [1] Group 3: Operational Efficiency - The company has implemented measures to optimize resource allocation and actively manage expenses, which have further enhanced operational efficiency [1] - The equity stake in the joint venture 4C Medical has decreased following its completion of Series D financing, resulting in recognized gains from the partial sale of shares [1]

Core Viewpoint - The company expects to achieve a net loss of no more than RMB 10 million in the first half of 2025, representing a year-on-year reduction of not less than 83% [1] Group 1: Financial Performance - The reduction in net loss is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its delivery system in over 20 countries/regions, with overseas revenue increasing by more than two times year-on-year [1] - The commercial progress of the AnchorMan® left atrial appendage occluder system and its guiding system in China is steadily advancing, having obtained CE marking and commercialized in Europe during the reporting period, contributing to revenue growth [1] Group 2: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which generated income from the sale of part of its equity [1]

Group 1 - The biopharmaceutical B-class stocks experienced a rally, with notable increases in stocks such as Clover Biopharma-B, Kelun-Biotech, and Xintong Medical-B, the latter seeing a peak increase of nearly 21% before settling at over 6% [2] - The surge in Xintong Medical's stock price is attributed not only to sector trends but also to the news that MicroPort Medical is considering merging its CRM business with Xintong Medical [2] - MicroPort Medical's stock also saw a significant increase, jumping nearly 7% on the same day [3] Group 2 - On July 16, Xintong Medical announced that its board received a non-binding proposal from its controlling shareholder, MicroPort Medical, regarding a strategic restructuring of the CRM business [4] - MicroPort Medical's CRM business focuses on developing, manufacturing, and selling products for diagnosing and managing arrhythmias and heart failure, including pacemakers and defibrillators [4] - The merger aims to enhance internal resource integration, improve competitiveness, and create long-term value for the group and its stakeholders [4] Group 3 - The merger is expected to create a comprehensive cardiac product platform, offering a diverse range of products from CRM solutions to structural heart disease products [6] - By establishing this diversified product platform, the group aims to enhance its global market development capabilities and strengthen its positioning in respective segments [6] - The merger is also anticipated to generate synergies through shared international marketing and sales channels, expanding business scale and growth potential [6] Group 4 - Overall, the merger represents an internal business adjustment for MicroPort Medical, aimed at consolidating cardiac-related operations and fostering collaborative development [7] - Both MicroPort Medical and Xintong Medical are currently in a loss-making position, and this restructuring may help them achieve profitability sooner [7] - Market feedback has been positive, with both companies' stock prices rising, although Xintong Medical's stock experienced a significant pullback, indicating some divergence in investor sentiment [8]